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Summary
The major characteristics of human atherosclerotic lesions are similar to those of a chronic
inflammatory reaction, namely fibrosis, mesenchymal cell proliferation, the presence of resident
macrophages, and cell necrosis. Atherosclerosis exhibits in addition the feature of lipid (mainly
cholesterol) accumulation. The results ofthe present report demonstrate that a specific cholesterol-
containing lipidparticle present in human atherosclerotic lesions activates the complement system
to completion. Thus, lipid could represent a stimulatory factor for the inflammatory reaction,
whose underlying mechanistic basis may be, at least in part, complement activation. The
complement-activating lipid was purified from saline extracts of aortic atherosclerotic lesions
by sucrose density gradient centrifugation followed by molecular sievechromatography on Sepharose
2B. It contained little protein other than albumin, was 100-500 nm in size, exhibited an unesterified
to total cholesterol ratio of 0.58 and an unesterified cholesterol to phospholipid ratio of 1.2.
The lipid, termed lesion lipidcomplement (LCA), activated the alternative pathway ofcomplement
in a dose-dependent manner. Lesion-extracted low density lipoprotein (LDL) obtained during
the purification procedure failed to activate complement. Specific generation of C3a desArg and
C5b-9 by LCA indicated C3/C5 convertase formation with activation proceedingto completion.
Biochemical and electron microscopic evaluations revealed that much of the C5b-9 present in
atherosclerotic lesions is membraneous, rather than fluidphaseSC5b-9. The observations reported
herein establish a link between lipid insudation and inflammation in atherosclerotic lesions via
the mechanism of complement activation.
therosclerosis shares in common with chronic inflamma-
1A tion the features ofleukocyte infiltration, fibrosis, mesen-
chymal cell proliferation, and tissue necrosis. Complement
plays a central role in many inflammatory and immune dis-
eases, and most of the complement components have now
been identified in human atherosclerotic lesions (1). Of par-
ticular importance is the presence of C5b-9 terminal comple-
ment complexes since their assembly indicates that comple-
ment activation with C3/C5 convertase formation has taken
place. The respective convertases cleave C3 and C5 gener-
ating the anaphylatoxins C3a and C5a, which in turn mediate
proinflammatory leukocyte functions (2). The C5b-9 com-
plex, in addition to its potential cytolytic effect, can influence
cell physiology in sublytic doses via activation of various
calcium-dependent pathways (3).
In a previous report, we demonstrated a temporal and spa-
tial colocalization of C5b-9 complexes and lipidin the aortic
tunica intima of cholesterol-fed rabbits (4). Lipid vesicles rich
in unesterified cholesterol are an early and consistent feature
of human and animal atherosclerotic lesions (5-11). In vitro,
liposomes containing a >50 mole percent of unesterified cho-
lesterol activate complement to completion (12, 13). We there-
fore suspected that lipidvesicles enriched in unesterified cho-
lesterol are capable of activating the complement system in
situ in the arterial wall. In this paper we describe the isola-
tion and characterization of a lipid particle extracted from
human atherosclerotic lesions and demonstrate its potent
complement-activating properties. The data establish a link
between the insudation of lipid and the inflammatory fea-
tures of atherosclerotic plaques.
Materials and Methods
Reagents and Antibodies.
￿
PBScontained 150 mM NaCl and 10
mM phosphatebuffer, pH 7.4. For transporting and washing tissues,
PBS was supplemented with 5 mM EDTA. Veronal-buffered saline
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CaC12, and 0.5 mM MgC12, pH 7.4.
Polyclonal rabbit antibodies against human: serum proteins; al-
bumin, C3; and apolipoprotein B were obtained from Dakopatts
(Copenhagen, Denmark). Polyclonal and monoclonal antibodies
against neoantigens of the C5b-9 complex were produced in our
laboratory (14, 15).
Humanlow-densitylipoprotein (LDL)waspurchasedfrom Sigma
Chemical Co. (Munich, FRG). Trypsin, chymotrypsin, staphaureus
protease, andneuraminidasewere purchasedfrom Worthington Bio-
chemicals Corp. (Freehold, NJ).
Tissue Specimens andExtraction.
￿
Carotid endarterectomy speci-
mens were obtained at surgery and transported to the laboratory
on ice in PBS/EDTA. After rinsing away residual blood, thetissue
was finely minced with a scissors using PBS as the extraction
medium (ti1 ml PBS per gram of tissue). The mincate was cen-
trifuged at 740g for 8 min. Theresulting supernatant was recen-
trifuged at 11,000 gfor 10 min and/or passed through a 0.45 Jim
filter to clear particulates. The final supernatant was then either
tested for complement-activating ability by immediately mixing
it with normal humanserum (NHS), or it was appliedto aSepharose
4B column (see chromatography methods below).
Human aortic tissue was obtained at autopsy 10-48 h afterdeath.
A longitudinal incision was made to expose the lumenal surface
of the aorta, whichwas then cleanedofresidualblood. Theintima
and inner tunica media were stripped-off to obtain predominantly
lesional tissue. Aortas with largeareasofgrossly normal tissue were
used to obtain control material. The intimal/medial tissue pieces
were finely minced with scissors, using PBS as the extraction
medium. After centrifugation at 740g, the supernatant was har-
vested and thetissue pellet wasre-extracted oneor twomore times
overnight at 4°C.
For both carotid and aortic specimens, tissue areas containing
calcification, thrombosis, or ulceration were omitted. 6carotid le-
sions and 15 aortic specimens were examined. Many extracts of
the aortic lesionswere eventually pooled. Patient ages at the time
of deathvaried from 27 to 91 yearswith the majority ofspecimens
deriving from patients in their seventh or eighth decade. Cause
of death was variable and the only causes of death omitted from
sample gathering were those due to highly infectious agents.
Sucrose Density Gradient Fractionation.
￿
Sucrosedensity gradients
ranging from 10 to 50% (wt/vol) were prepared in 20 mM Tris-
HCl, 100 mM NaCl, pH 8.0 (35 ml total volume) and 5 ml of
lesion extract was applied to the top of each gradient. Centrifuga-
tion wasperformed at 240,000 g for 3 h (4°C) in a vertical rotor
(typeVTi-50; Beckman Instruments, Fullerton, CA). 10 equalfrac-
tions were then collected for further analyses.
Molecular Sieve Chromatography.
￿
Carotid lesion extracts were
fractionated on a 0.9 x 60 cm Sepharose 4B column (Pharmacia
Fine Chemicals, Uppsala, Sweden) and eluted with 1.5 M NaCl
containing 5 mM EDTA and 15 mM NaN3, pH 7.4, at 4°C. 1-ml
fractions were collected and the flow rate was 8ml/h. Aortic lesion
extracts were either directly applied to a 2 x 100 cm Sepharose
2B column or first fractionated by sucrose density gradient cen-
trifugation andthen applied to thecolumn. In thelatter case,pooled
fractions 9 and 10 from the sucrose gradient were used. The flow
rate was 25 ml/h and 8-9-ml fractions were collected.
No qualitative or striking quantitative differences were observed
in the fractionation of lipid or complement components relative
t Abbreviations used in this paper: LCA, lesion lipid complement
activator; LDL, low density lipoprotein; NHS, normal human serum;
VBS, veronal-buffered saline.
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to the source of tissue used for extraction or the columns used.
Fractionsfrom theSepharose 2B column containing complement-
activating activity were pooled and concentrated 15-25-fold by
ultrafiltrationusingFiltron omegacells (Filtron, Karlstein, FRG).
This concentrate represents the purified lesion lipid complement
activator (LCA).
Electroimmunoassays.
￿
Rocket andfusedimmunoelectrophoresis
of fractionated lesion extract was performed in the conventional
manner using 1% (wt/vol) Litexagarose (type HSA; Copenhagen,
Denmark) dissolved in 0.1 M glycine, 0.038 M Tris, pH 8.7 .
Immunoelectrophoresis wasperformed in thesame buffer system
at 2-3 V/cm, overnight. For analysis of fractions collected from
the Sepharosecolumn, the application wassupplemented with 0.2%
Triton X-100 in order to liberate proteins from the lipidparticles.
Detergent was not added to the antibody-containing gels. SDS-
PAGE and immunoblotting were performed as described (15).
Complement Activation Tests.
￿
Generally, one volume of sample
was incubated with one volume of fresh human serum at 37°C
for 45-60 min. Fractionsrecovered from the sucrose gradients were
dialysed against VBS2* overnight at 4°C prior to testing. Due to
their lower LCA content, fractions from the Sepharose columns
were admixed with only one-tenth the volume of NHS.
Complement Assays.
￿
C3a desArg was measured using a radio-
immunoassay kit supplied by Amersham (Braunschweig, FRG).
TheC5b-9complexwas quantified by an ELISA as described (15).
Concentrations were calculated on thebasisof theoriginal volumes
of NHS present in the reaction mixtures.
Lipid Analysis.
￿
Cholesterol andtriacylglycerides were measured
using commercial kits from Boehringer Mannheim (Mannheim,
FRG). Standard curves were generated using the lipid standards
provided by the same company.
Fatty Acid Analyses.
￿
Long chain fatty acids were analyzed by
gas-liquid chromatography (GLC) and combined gas-liquid chro-
matography/mass spectrometry (GLC-MS). The dialyzed and
lyophilized sample (2.5 mg) was dissolved in 2.5 ml of 4 M HCl
and 25 leg of heptadecanoic acid (17:0) was added to serve as an
internal standard. The mixture was hydrolyzed (100°C, 4 h) and
thefattyacidswere extracted three timeswith 3ml of chloroform.
The organic layers were combined, dried over Na2S04, and finally
concentrated under a stream of nitrogen. After esterification with
diazomethanein ether (Diazald,AldrichChemical Co., Milwaukee,
WI), thesample was concentrated againandan aliquot (1/20) was
subjected to GI.C analysis. GLC was carried out on a gas-
chromatograph (model 3700; Varian Associates, Palo Alto, CA)
equipped with a fused silica capillary column (25 m, 0.2 mm in-
ternal diameter) with chemical bonded SE-54. The temperature
program was set to 150°C for 3 min, then raised to 250°C at a
rate of 3°C/min. The amounts of the fatty acids were calculated
on the basis of peak areas relative to the internal standard (17:0).
GLC-MS wasperformedon a5890Agas-chromatographequipped
with a 5970 mass selective detector (Hewlett-Packard Co., Palto
Alto, CA) using the same temperature program as for GLC.
Amino Acids, Amino Sugars, and Ethanolamine.
￿
Amino acids,
amino sugars, and ethanolamine were liberated from 2 mg of the
LCA by acid hydrolysis in 2.5 ml of 6 M HCl (100°C, 16 h) in
sealed ampules, They were then identified and quantitated by an
amino acid analyzer (Alpha Plus 4151, LKB-PharmaciaFine Chem-
icals, Piscataway, NJ) using post-column derivatization with nin-
hydrin.
Electron Microscopy: Negative Staining.
￿
Samples of LCAin PBS
were applied to thin carbon-coatedFormvarfilmscarried on copper
grids, exposed to glow-discharge in atmospheric air shortly before
use, and negatively stained with 2%ff sodium silicotungstate, pH7.0 (16). Attempts to demonstrate the presence of cholesterol by
reaction with filipin were performed as follows. Filipin (batch U
5956, obtained as a gift from the Upjohn Company, Kalamazoo,
MI) was dissolved in DMSO (50 ul/mg) and diluted with PBS
to a final concentration of 4 mg/ml. Aliquots ofLCA in PBS were
mixed with this filipin solution at final filipin concentrations of
0.8, 1.2, 1.6, and 2.0 mg/ml, and left to stand in the dark at 23°C
for 1 h before negative staining. Other aliquots were incubated
with trypsin or a-chymotrypsin (type II; Sigma Chemical Co.,
St . Louis, MO) in PBS, pH 8.0, at individual enzyme concentra-
tions of 0.1 mg/ml for 1 h at 23°C.
Electron Microscopy: Thin Sectioning.
￿
LCA in PBSwas mixed with
an equal volume of 2% OS04 in 0.2 M sodium cacodylate buffer,
pH 7.0, and left to stand for 15 min at 23°C. It was then cen-
trifuged at 10,000g for 30 min in volumes of 150 1A1with a sedimen-
tation distance of 5 mm. The resulting pellets were dehydrated in
ethanol, followed by propylene oxide, and embedded in Epon 812.
Ultrathin sections were cut on a diamond knife and stained with
uranyl acetate and lead citrate.
Electron Microscopy:Freeze-FractureReplication.
￿
LCA in PBS was
mixed with an equal volume of 60% glycerol, mounted as drops
on gold stubs, and frozen in Freon 22, cooled in liquid nitrogen.
In addition, some LCA specimens were frozen without the addi-
tion of glycerol. Negative staining ofglycerinated samples showed
no detectable structural changes ofthe LCA relative to nonglyceri-
nated samples. Freeze-fracture was performed by standard techniques
in a Balzers 301 unit (17).
All electron microscope specimens were examined and pho-
tographically recorded in a JEOL 1000X electron microscope
equipped with an ultra high resolution objective lens pole piece
(Cs 0.7 mm), operated at 80 kV
Results
Atherosclerotic Lesion Extracts Activate Complement in Normal
Human Serum. Terminal C5b-9 complementcomplexes have
been detected in human atherosclerotic lesions by im-
munochemical techniques (18-20), thus implicating in situ
activation of complement. However, direct demonstration
of complement activation by lesion material has not been
shown, nor has the element(s) responsible for triggering ac-
tivation been identified. We therefore prepared saline extracts
of freshly removed carotid artery atherosclerotic lesions and
incubated them with normal human serum (vol/vol) at 37°C
for 60 min. After subtracting out baseline (time 0) levels and
the nonspecific generation of C3a in serum incubated with
buffer alone, 13.3 ± 4.5 lag/ml of C3a desArg was found
to have been generated. Each sample preparation was similar
in terms of the tissue weight (0.6-0.8 g), extraction volume
(1 ml), and cholesterol concentration (243 ± 44 Fog/ml). The
extracts were viewed by light microscopy and found to con-
tain few, if any, crystals.
The generation of C3a in serum mixed with lesion extract
indicated that a component(s) is present in atherosclerotic
lesions that can generate C3 convertases. Extracts of normal
arterial tissue failed to generate significant amounts of C3a
under the same conditions. Without exception, however, ex-
tracts obtained from 15 atherosclerotic aortic lesions exhibited
similar complement activating properties as the material de-
rived from freshly isolated carotid lesions.
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Isolation of a Lipid from Extracts that Activates Comple-
ment. To determine the lesional component(s) responsible
for triggering complement activation, saline extracts of aortic
atherosclerotic lesions were fractionated by sucrose density
gradient centrifugation. Fig. 1 depicts the characteristic frac-
tionation profile for lipid, protein, apoprotein B, complement
component C3, and the C5b-9 complex. The pattern was
invariant between all the samples analyzed and exhibited only
minor quantitative differences from sample to sample. Lipid,
as measured by cholesterol (Fig. 1, A), immunoreactive
apoprotein B (Fig. 1 B), and triacylglycerides (data not shown),
floated at the top of the gradient and was therefore detected
in fractions 9 and 10. The bulk of the protein was present
in fractions 6-9 (A and C), and C3 was identified in frac-
tions 7 and 8 (D). The C5b-9 complex sedimented towards
the bottom of the gradient, exhibiting a peak in fraction 3
(E). The sedimentation behavior of this entity differed from
that of fluid-phase SC5b-9, which peaked in fraction 5, cor-
responding to 23 S in these gradients (position indicated by
an arrow in Fig. 1).
To determine whether a specific lesion component was
present that could activate complement, each fraction from
the sucrose density gradient was dialyzed against VBS2+ and
reacted with NHS. It was found that fraction 10, and to a
lesser extent, fractions 6 and 7, exhibited the capacity to acti-
vate complement as assessed by the specific generation ofC3a
desArg (Fig. 2). The top fractions (9 and 10) containing the
bulk ofactivity were applied to a Sepharose 2B column. The
resulting elution profile, which was typical of all aortic spec-
imens examined, is shown in Fig. 3. A lipid peak devoid of
apoprotein B eluted in the void volume, whereas the majority
of protein was detected towards the included (end) volume
(Fig. 3, A-C). A small apoprotein B immunoreactive peak
was observed towards the end volume (C); however, choles-
terol could not be detected in these fractions without prior
concentration.
When each fraction from the Sepharose column was reacted
with serum, a peak of complement-activating activity was
observed that coincided with the void volume peak (Fig. 3
D). Fractions containing the void volume peak were pooled
and concentrated 15-25-fold. This pool constitutes the puri-
fied lesion LCA. In addition, the fractions containing the
apoprotein B peak were pooled and concentrated. Both of
the pooled concentrates were subsequently analyzed for cho-
lesterol and tested for their complement-activating capacity.
As shown in Fig. 4, the LCA activated serum complement
in a dose-dependent manner. Half-maximal C5b-9 levels oc-
curred at a final LCA/cholesterol concentration of -0.25
mg/ml, and specific C5b-9 generation was still observed at
LCA/cholesterol levels as low as 0.06 mg/ml. In contrast,
the rear, apoprotein B-containing peak from the column failed
to activate complement even when the amount of cholesterol
added was 0.7 mg/ml.
Further experiments were undertaken to determine whether
LDL or modified LDL has the potential to activate serum
complement. Kinetic and dose-response experiments wereper-
formed with purified LDL wherein the LDL was incubated
in Hams F-10 media containing 5 /AM CUS04 or with cul-Figure 1 .
￿
Sucrose density gradient profile of aortic atherosclerotic
lesion extract . Fresh lesion extract (5 ml) was layered onto a 10-50%
sucrose gradient (35 ml) . After centrifugation, 10 equal fractions of
4 ml were collected. Cholesterol was detected biochemically in frac-
tions 9 and 10 (A) . Rocket immunoelectrophoresis demonstrated : the
presence of apoprotein B in fractions 9 and 10 (B); serum proteins
predominantly in fractions 7-9 (C) (which corresponded well with
total protein determined biochemically [A]) ; and complement C3 in
fractions 7 and 8 (D) . The C5b-9 complex (measured by ELISA)
sedimented towards the bottom o£ the gradient peaking in fraction
3 (E) . The sedimentation position of purified SC5b-9 (23 S) is
depicted by an arrow.
tured human endothelial, monocyte, or vascular smooth
muscle cells to induce oxidative/degradative changes (21-24) .
Additionally, purified LDL (500 Fig/ml) was subjected to treat-
ment with : trypsin (50 jig/ml), chymotrypsin (50 ttg/ml),
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Figure 2 .
￿
The complement-activating capacity of fractionated
atherosclerotic lesion extract . All 10 fractions collected from the su-
crose density gradient were dialysed against VBS 2* and mixed with
normal human serum (vol/vol) for 60 min at 37°C . The specific C3a
desArg generated in the serum was then measured by RIA .
neuraminidase (27 U/ml), staphaureus protease (100 gg/ml),
or cholesterol esterase (2.5 U/ml) . Under none of these cir-
cumstances was complement-activating activity ever observed
upon addition ofLDL or modified LDL to NHS (final con-
centration of maximal LDL/cholesterol, 0.5 mg/ml) .
Characteristics ofComplementActivation byLCA .
￿
The dose-
response relationship of LCA-mediated complement activa-
tion was alluded to above and shown in Fig . 4 . In the experi-
ment depicted in Fig. 5, LCA was added to NHS to yield
a final LCA/cholesterol concentration of 0.75 mg/ml, and
the kinetics of complement activation were studied . C3a
desArg levels peaked rapidly, reaching a plateau within 30
min (corresponding to 30-40 kg/ml C3a desArg production) .
C5b-9 generation was slower and more sustained, reaching
a plateau at -60 min (Fig . 5) . The relative efficiency of the
terminal sequence activation was high, with molar ratios of
C3a to C5b-9 approaching 20:1, typical of complement acti-
vation on particulate surfaces (25) . C5b-9 levels were remark-
ably high in the extract-reacted serum samples, reaching levels
exceeding 300 kg/ml SC5b-9, when calibration curves were
generated with purified SC5b-9 . Preliminary results indicate
that a substantial portion of the C5b-9 generated by LCA
is in the form of C5b-9(m) complexes. Membranous C5b-9
exhibits a higher reactivity in the ELISA as compared with
SC5b-9 complexes (15) (used as the calibrating standard
throughout) . The present values may therefore represent over-
estimates of the true C5b-9 levels .
The ability ofLCA to activate complement did not change
upon standing for up to several weeks at 4°C . There was
no difference in the complement-activating capacity ofLCA
isolated from aortas obtained 10 h after death as compared
with those obtained 48 h after death. These results indicate
a high stability of the LCA particle and its complement-
activating property. They also argue that oxidative and/or
proteolytic modifications are not involved in generating or
rendering this lipid particle a complement activator .Figure 3 .
￿
Molecular sieve chromatography of the complement-
activating fractions from the sucrose density gradient . Fractions 9 and
10 were applied to a 20 x 100 cm Sepharose 2B column and eluted
with VBS2* . Fractions of 8 ml were collected and analyzed by rocket
immunoelectrophoresis for serum proteins (A) ; albumin (B) and ;
apoprotein B (C) . Cholesterol was detected biochemically and found
to elute in the void volume (D) . Each column fraction was mixed
with normal human serum for 60 min at 37°C and the degree of
complement activation was assessed by measuring the C5b-9 gener-
ated . A C5b-9 peak was evident that coincided with the void volume
lipid peak (D) .
To test whether complement activation occurred via the
classical or alternative pathway, activation tests were conducted
in the presence of 2mM Mgz+ and 5 mM EGTA . Comple-
ment activation was found to occur to an undiminished de-
gree despite blockade of the classical pathway, indicating a
predominant involvement of the alternative pathway.
Characterization ofthe LCA .
￿
The LCA exhibited an un-
esterified to total cholesterol ratio of 0.58, a small amount
of triacylglyceride, and an unesterified cholesterol to phos-
pholipid ratio of 1.2 (Table 1) . When extracted with chloro-
form/methanol, 95% by weight of the LCA partitioned to
the organic phase . Phospholipids and cholesterol accounted
for43% by weight of the organic phase material . Palmitate,
oleate, linoleate and most likely, nervonic acid (or nervonate)
constituted the major fatty acids esterified to phospholipid
(the technique did not permit analysis ofcholesterol esterified
fatty acids) (Table 1) . The residual material represented a mix-
ture of amino acids that were not further differentiated .
A mixture of amino acids plus two amino sugars, glucosa-
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Figure 4 .
￿
The dose-response relationship of LCA-mediated comple-
ment activation. Varying concentrations ofLCA were mixed with
normal human serum for 60 min at 37°C and the amount of C5b-9
generated was quantitated by an ELISA . C5b-9 values were calculated
from a standard curve generated with purified SC5b-9 complexes. In
the same experiment, the pooled concentrated apoprotein B peak
from the Sepharose 2B column was analyzed and found to generate
no C5b-9 .
mine and galactosamine, were detected in the water phase
of the chloroform/methanol extracts.
As depicted in Fig. 3 B, the major immunoprecipitable
serum protein present in the LCA Sepharose 2B column frac-
tions was albumin . In SDS-PAGE, a single major protein band
of 68,000 daltons was observed in the LCA material (Fig.
6) and was identified as albumin by immunoblotting using
antialbumin-specific antibodies (data not shown) . A number
of faintly staining protein bands were also observed that have
not been identified. No immunoprecipitation was observed
when concentrated LCA was solubilized with 0.2% Triton
X-100 and double diffusion was performed using antibodies
against apoprotein B.
Ultrastructural Analyses ofLCA .
￿
By far the dominating
component of the LCA preparations observed in negative
staining were spherical lipid particles, mostly 100-500 nm
in diameter. These particles exhibited a characteristic blurred
contour that distinguishesthem from liposomes bounded by
phospholipid bilayers, which exhibit sharp surface boundaries .
Typical liposomes were present only in minute amounts (Fig .
7A) . Examination of a series offractions from the Sepharose
columns used for the purification of the LCA revealed that
the particles with blurred contours were confined to the
strongly complement-activating fractions, and these particles
will henceforth be referred to as the specific LCA particles.
Most of these particles carried on their surface tufts of non-400 r
300
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Figure 5 .
￿
The kinetics of LCA and inulin-mediated complement
activation. LCA was mixed with normal human serum at a final cho-
lesterol concentration of 0.75 mg/ml . The amounts of C3a desArg
and C5b-9 generated were determined at varying time intervals.
lipid material (Fig. 7 A) . This material appeared loosely as-
sociated with the particles, evidenced by the finding of such
material in partially or fully detached form . Incubation with
Table 1 .
￿
Hydrophobic Constituents of the Lipid Complement
Activator
Approximately 10 mg (cholesterol) of purified LCA was chloro-
form/methanol extracted and analyzed by GLC and GLC-MS . All
lipids shown were present in the organic phase of the extracts . Only
fatty acids with concentrations of 35 Wg/mg are shown .
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Figure 6.
￿
SDS-PAGE of purified
LCA . A single band at 68 kD was
stained with Coomassie Blue under
reducing conditions (lane b) . Several
weakly staining bands were observed
of varying molecular mass. Molec-
ular mass markers are shown in lane
a (from top : 205,000; 92,000; 60,000 ;
43,000 ; 29,000) .
trypsin and a-chymotrypsin did not remove this material to
a detectable extent .
Incubation of the specific LCA particles with filipin failed
to result in the development ofcharacteristic filipin-cholesterol
complexes . A few filipin lesions were observed associated with
the sporadic phospholipid bilayer structures in the prepara-
tions. At the higher filipin concentrations applied, the specific
LCA particles tended to dissolve .
The nonbilayer organization of the specificLCA particles
was confirmed in the thin sections where the dominating
structures were hollow "bodies" bounded by a 20-50 nm
broad rim with no apparent bilayer configuration and with
poor staining properties relative to the multilamellar phos-
pholipid structures that were found sporadically in the sec-
tions (Fig. 7 B) . Many of the hollow bodies carried tufts of
weakly stained material on the surface . The hollow bodies
were most probably identical with the specificLCA particles
observed by negative staining. The density of their interior
was identical to that of the background, suggesting that they
were indeed hollow. It could not be excluded, however, that
they contained lipid that was not preserved by the fixation,
and accordingly was extracted in the embedding procedure.
Freeze-fracture replication of LCA preparations demon-
strated almost exclusively smooth fracture faces (Fig. 7 C) .
A few of the particles were seen in cross fracture, and ap-
peared to have solid nonaqueous cores. These particles could
represent a less common subpopulation of lipid particles .
Analysis ofFresh Plaque Extract.
￿
To further exclude that
theLCA represents a post-mortem artifact, endartectomy spec-
imens (n = 4) were extracted into PBS and directly applied
to a Sepharose 4B column . Two lipid peaks were again resolved
(Fig . 8) . The void volume peak exhibited the same lipid char-
acteristics as that found for the LCA, i .e ., the unesterified
to total cholesterol ratio was -0.5, and no apoproteinB could
Cholesterol and phospholipid Fatty acids
pg/mg Fig/mg
Cholesterol total 287.0 Myristic 14.0 9.5
(TC) Palmitic 16.0 40.2
Cholesterol
unesterified (UC) 167.8 Stearic 18.0 5.0
Phospholipid 137.7 Oleic 18.1 24.9
UC/TC 0.58 Linoleic 18.2 12.4
UC/PL 1.20 Arachidonate 20:1 5.8
Lignoceric 24 :0 5.0
Nervonic 24.1 13.7be detected . The second lipid peak eluted in the same frac-
tions as did purified LDL (data not shown), reacted with
polyclonal antibodies to apoprotein B (Fig. 8), and exhibited
a lipid composition similar to that ofLDL (unesterified to
total cholesterol ratio of 0.32) . Both the crude extract and
the void volume peak eluting from the Sepharose 4B column
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Figure 7 .
￿
(A) Negatively stained
preparations of purified LCA from
Sepharose 2B fractions 14-16. The
dominant constituent is lipid parti-
cles with a characteristic blurred
contour (a) . Some of these parti-
cles (b) are associated with non-
lipid material, which may be found
detached from the particles as well
(c) . Sharply contoured particles
(arrow), probably bordered by a
phospholipid bilayer, are found
only as a minor constituent in
these fractions. (B) Thin sections
of the same preparation . The
major constituent is represented by
hollow bodies (L) bordered by a
broad rim, whose dimensions and
staining properties differ from that
of phospholipid bilayers, that may
be found sporadically as multi-
lamellar particles (P). (C) Freeze-
fracture replication of the same
LCA preparation showing mostly
smooth fracture faces. Irregularities
in the fracture face (arrow) are oc-
casionally seen, that may represent
irregularities in lipid structure
rather than incorporated non-lipid
material . Cross-fractures of parti-
cles revealing a solid nonaqueous
core (S) are rare and may represent
a subpopulation of particles. Scale
bars indicate 200 nm .
exhibited complement-activating activity similar to that found
for the LCA derived from aortic lesions .
Presence of Membranous C5b-9 Complexes in Atherosclerotic
Lesions. C5b-9 neoantigens were detected in the high mo-
lecular weight fractions of the sucrose density gradients (Fig.
1) . When this material was analyzed by SDS-PAGE/immu-Figure 8 .
￿
Elution profile o£ carotid artery atherosclerotic lesion ex-
tract fractionated on a 0 .9 x 60 cm Sepharose 4B column .
Apoprotein B was detected by rocket immunoelectrophoresis (A) .
Cholesterol was detected biochemically (B) .
noblotting, both C8 and C9 components were detected (Fig.
9) . Some nonspecific staining of protein bands was observed
(high molecular weight band in lane b, Fig. 9A, and bands
below C80 and C9 in the lanes of both blots), the origins
of which were not investigated . No bands developed when
the primary antibodies were omitted (not shown) . There was
a conspicuously strong staining of the C9 dimer (C92),
which is virtually absent in fluid-phase SC5b-9 (Fig. 9 B,
lane a, and reference 26) andwhose presence is characteristic
ofmembrane C5b-9 complexes (26) . Fluid-phase SC5b-9 was
analyzed for comparison (Fig. 9, lane a), and it is apparent
that the major C8 andC9 protein bands correspond to those
detected in the plaque extract . When the high molecular
weight fractions of the sucrose density gradients were exam-
ined by electron microscopy, they were found to contain large
quantities ofmorphologically characteristic cylindrical C5b-
9(m) complement complexes. Many of these carried a girdle
of material at their terminus . The bottom fractions (1 and
2, Fig . 1) contained fragments of membranes carrying mas-
sive numbers of C5b-9(m) complexes (Fig. 10, B and C) . In
fractions 3 and 4, M-9(m) was present mostly as single
cylinders (Fig . 10 A) . C5b-9(m) complexes were also sporad-
ically found in very low numbers in the preparations ofspecific
LCA particles (not shown) .
Discussion
This paper describes the isolation and characterization of
a complement-activating lipid particle from extracts ofhuman
atherosclerotic lesions. The lipid, termed LCA, contained no
immunoreactive apoprotein B, was 100-500 nm in size, ex-
hibited a unesterified to total cholesterol ratio of 0.58, and
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Figure 9 .
￿
C8 and C9 analysis of lesion extracted C5b-9 complexes
by SDS-PAGE followed by immunoblotting. Fraction 3 from sucrose
density gradient fractionation (contains C5b-9 complexes, see Fig. 1
and 10) was analyzed for C8 (A, lane b) and C9 (B, lane b) using
the respective antibodies . Purified SC5b-9 complexes were analyzed in
parallel (lanes a) for comparison . The subunits within the terminal
complex have been previously identified (3, 34) .
an unesterified cholesterol to phospholipid ratio of 1.2 . The
LCA activated the alternative complement pathway in a dose-
dependent manner. Kinetic studies revealed that C5b-9 com-
plex formation was slower than C3a generation, implying
that the C5 convertase was stabilized and/or there was a delay
in its formation . In addition to the LCA, one other major
lipid particle was isolated from lesion extracts. This lipid had
the characteristics ofLDL and was not an activator of com-
plement, nor could we make purified LDL into an activator
by a variety of oxidative or enzymatic means. Since the vast
majority of lesion-deposited lipid is derived from LDL, it
would appear that within the arterial wall a profound meta-
bolic and physiochemical transformation of LDL occurs,
resulting in the evolution of a unique lipid particle capable
of activating complement .
Several features of the composition of the LCA suggest
that its complement-activating capacity derives from its high
content of unesterified cholesterol . Unesterified cholesterol
in the crystalline state activates the alternative pathway of com-
plement via an interaction between complement component
C3 and the free hydroxyl group ofcholesterol (27, 28) . Lipo-
somes containing a greater than, but not less than, 50 mole
percent unesterified cholesterol spontaneously activate the al-
ternative complement pathway in vitro (12, 13) . Data have
been reported indicating that unesterified cholesterol in equi-
molar concentration with phospholipid sequesters to form
patches of liquid crystalline structure (29, 30) . Hence, it is
possible that on the surface of the LCA, the free hydroxyl
groups of cholesterol are clustered, thus providing a site for
C3 convertase formation .
Regarding possibilities other than unesterified cholesterol
as responsible forLCAmediated complement activation, pro-
tein is highly unlikely since albumin was the only protein
detected in significant quantities. By electron microscopy a
material was observed adherent to the LCA that is probably
glycosaminoglycan and/or proteoglycan . This was also sug-gested by the detection of amino sugars in the water phase
ofLCA chloroform/methanol extracts. Lipid particles are well
known to exhibit an affinity for glycosaminoglycans and pro-
teoglycans (31) and have been demonstrated in void volume
lipid fractions of lesion extracts (10) . Treatment of the LCA
with chondroitinase ABC did not, however, interfere with
its complement-activating properties (data not shown) . This
suggests that these substances, if present, were not respon-
sible for the activation of complement . Furthermore, glycos-
aminoglycans derived from human atherosclerotic lesions (kind
gift ofDr. German Camejo, Gothenburg, Sweden) did not
activate complement alone or in combination with LDL (data
not shown) .
Large lipid particles (70-300 nm in diameter) rich in un-
esterified cholesterol have been isolated from human and rabbit
atherosclerotic lesions by Chao et al . (10) ; however, certain
characteristics ofthese particles differ from whatwe observed
with the LCA . For example, the LCA unesterified choles-
terol to phospholipid ratio was 1.2, whereas that described
byChao and colleagues was roughly twice that amount . Ad-
ditionally, their particles were reported to exhibit uni- and
multilamellar phospholipid membrane structure and form
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Figure 10.
￿
Electron microscopic
examination of C5b-9 complexes
present in fractionated lesion ex-
tract . (A) Negative staining of su-
crose density gradient fraction 4
(see Fig. 1) demonstrating many
single copies of cylindrical C5b-
9(m) complexes (arrows) . (B and
C) Bottom fractions 2 and 3 of
the sucrose density gradients con-
tain many membrane fragments
carrying M-9(m) complexes
(arrows), sometimes in massive
numbers (C) . Scale bars indicate
100 nm .
complexes with filipin to form the characteristic lesions . The
latter differencemay in fact be related to the absence of bilayer
structure in the LCA, which may in turn be related to its
phospholipid content .
One possible explanation for the dissimilarities between
the particles described herein and those found by others is
that different subpopulations within a larger, heterogeneous
population have been isolated due to differences in the tech-
niques used. The results of Chao et al . support this possi-
bility in that within their large (70-300 nm) lipid fraction,
they found subpopulations with significantly different lipid
compositions after saline density gradient centrifugation (10) .
Fractionation of lesion extracts by sucrose density gradient
centrifugation revealed that C3, C5b-9, and lipid did not
cosediment (Fig . 1) . This does not necessarily contradict the
finding that lipid represents the major complement-activating
entity in lesions. Several studies have demonstrated, for ex-
ample, that the majority ofcleavedC3 formed during activa-
tion is released into the fluid phase, and that for certain acti-
vators, little if any C3 becomes bound to the activator (32,
33) . Furthermore, activated C3 is rapidly degraded by specific
complement regulatory proteins, several of which are knownto be present in human atherosclerotic lesions (20). Also, since
lesion macrophages possess receptors for C3b and iC3b (20),
opsonized lipidmight be expected to be phagocytosed. Hence,
the fraction of lipid in a plaque carrying bound C3 might
be below the detection limits of our assay procedures.
Regarding the C5b-9 complex, there is as yet no evidence
that it would remain associated with the lipid particles fol-
lowing assembly at their surfaces. Of significance is the fact
that LCA may not be bounded by a lipid bilayer into which
C5b-9 insertion could effectively occur. In this connection,
it is noteworthy that C5b-9(m) complexes purified from target
membranes can post-bind S protein, resulting in the appear-
ance of a girdle of material (presumably the S-protein) at the
apolar terminus of the cylinder (34). Such girdles were regu-
larly observed on free C5b-9(m) complexes present in frac-
tionated lesion extracts (Fig. 7). Thus, C5b-9(m) may first
assemble on the LCA but then dissociate to bind S-protein.
That C5b-9(m) formson the
I
CA and subsequently dissociates
was also suggested by the kinetics of LCAmediated comple-
ment activation, the strong reaction ofC5b-9 in the ELISA,
and the finding of occasional C5b-9 complexes in the LCA
fractions.
The origin(s) of C5b-9 aggregates attached to membrane-
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